Long COVID and the Autonomic Nervous System: The Journey from Dysautonomia to Therapeutic Neuro-Modulation through the Retrospective Analysis of 152 Patients

  • Joseph Colombo
    Franklin Cardiovascular, Autonomic Dysfunction and POTS Center, Sicklerville, NJ 08081, USA
  • Michael I. Weintraub
    Department Neurology and Medicine, New York Medical College, Valhalla, NY 10595, USA
  • Ramona Munoz
    Franklin Cardiovascular, Autonomic Dysfunction and POTS Center, Sicklerville, NJ 08081, USA
  • Ashish Verma
    Franklin Cardiovascular, Autonomic Dysfunction and POTS Center, Sicklerville, NJ 08081, USA
  • Ghufran Ahmad
    Franklin Cardiovascular, Autonomic Dysfunction and POTS Center, Sicklerville, NJ 08081, USA
  • Karolina Kaczmarski
    Franklin Cardiovascular, Autonomic Dysfunction and POTS Center, Sicklerville, NJ 08081, USA
  • Luis Santos
    New Jersey Heart, Sicklerville, NJ 08081, USA
  • Nicholas L. DePace
    Franklin Cardiovascular, Autonomic Dysfunction and POTS Center, Sicklerville, NJ 08081, USA

説明

<jats:p>Introduction. The severity and prevalence of Post-Acute COVID-19 Sequela (PACS) or long-COVID syndrome (long COVID) should not be a surprise. Long-COVID symptoms may be explained by oxidative stress and parasympathetic and sympathetic (P&S) dysfunction. This is a retrospective, hypothesis generating, outcomes study. Methods. From two suburban practices in northeastern United States, 152 long COVID patients were exposed to the following practices: (1) first, they were P&S tested (P&S Monitor 4.0; Physio PS, Inc., Atlanta, GA, USA) prior to being infected with COVID-19 due to other causes of autonomic dysfunction; (2) received a pre-COVID-19 follow-up P&S test after autonomic therapy; (3) then, they were infected with COVID-19; (4) P&S tested within three months of surviving the COVID-19 infection with long-COVID symptoms; and, finally, (5) post-COVID-19, follow-up P&S tested, again, after autonomic therapy. All the patients completed autonomic questionnaires with each test. This cohort included 88 females (57.8%), with an average age of 47.0 years (ranging from 14 to 79 years), and an average BMI of 26.9 #/in2. Results. More pre-COVID-19 patients presented with sympathetic withdrawal than parasympathetic excess. Post-COVID-19, these patients presented with this ratio reversed and, on average, 49.9% more autonomic symptoms than they did pre-COVID-19. Discussion. Both parasympathetic excess and sympathetic withdrawal are separate and treatable autonomic dysfunctions and autonomic treatment significantly reduces the prevalence of autonomic symptoms. Conclusion. SARS-CoV-2, via its oxidative stress, can lead to P&S dysfunction, which, in turn, affects the control and coordination of all systems throughout the whole body and may explain all of the symptoms of long-COVID syndrome. Autonomic therapy leads to positive outcomes and patient quality of life may be restored.</jats:p>

収録刊行物

  • NeuroSci

    NeuroSci 3 (2), 300-310, 2022-05-23

    MDPI AG

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ